Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8899522 | 0.76 | RXFP1 (0.43) | KDM4EMAPTRXFP1 | |
| SCHEMBL1115437 | 0.73 | BRPF1 (0.38) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL8898917 | 0.73 | KMT2A (0.48) | KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL1113031 | 0.72 | XDH (0.41) | — | |
| SCHEMBL12320558 | 0.68 | KIF11 (0.36) | — | |
| SCHEMBL12320518 | 0.68 | KIF11 (0.36) | — | |
| SCHEMBL12320842 | 0.67 | KIF11 (0.44) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL8897533 | 0.66 | PSMB8 (0.38) | KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL12278046 | 0.63 | KIF11 (0.32) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL28129146 | 0.62 | XDH (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377941-B2 | Indoles as modulators of nicotinic acetylcholine receptor subtype alpha-7 | PROXIMAGEN LIMITED (GB) | 2013-02-19 | — | — | US | disclosed |
| US-20110028486-A1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | GLAXOSMITHKLINE SERVICES UNLIMITED (GB) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028486-A1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | CHRNA7, CHRNA5, CHRNA6 | KDM4E 2285/4885ALDH1A1 1710/4885HPGD 2106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.